Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineAetna pediatric obstructive sleep apnea Coverage |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0752

    Obstructive Sleep Apnea in Children

    Customize your policy alerts

    Sign up for Aetna Policy 0752 alerts

    Get alerted when Policy 0752 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy describing medical necessity, covered and not-covered diagnostic and treatment modalities for pediatric obstructive sleep apnea (children and adolescents), and applicable coding guidance for providers and payers.

    Policy Summary
    PayerAetna
    PolicyObstructive Sleep Apnea in Children
    Policy CodePolicy 0752
    Change TypeNo material clinical or coverage changes
    Effective DateApr 25, 2008
    Last ReviewDec 13, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain and document attended nocturnal polysomnography (NPSG) in a facility to support diagnosis or post‑operative assessment and meet coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    NPSGNPSG gold standard
    >10 & <50UAS AHI eligibility
    13–18UAS age window
    25+Experimental modalities
    65.9%HNS 12‑month AHI ≥50% redn

    Coverage Criteria

    inv-03: Hypoglossal nerve neurostimulation (UAS) — adolescents with Down syndrome — Covered when ALL of the following are met.

    Hypoglossal Nerve Stimulation (pediatric Down syndrome): evidence supporting FDA approval and clinical outcomes from pivotal study.

    FDA approval expanded to include pediatric patients ages 13–18 years with Down syndrome and AHI >10 to <50 who meet the device-specific anatomic and treatment-failure criteria.
    In a clinical study of 42 adolescents with Down syndrome and OSA treated with Inspire UAS, 12‑month outcomes included: 65.9% of patients with ≥50% reduction in AHI; 73.2% with AHI <10 events/hour; mean Epworth Sleepiness Scale reduction of 5.1 points (mean ESS from 10.0 to 5.0). These data, together with adult trial (STAR) results and real‑world ADHERE registry evidence, supported the FDA indication expansion.

    inv-12: RME: covered_with_caveats — RME — evidence summary and recommended cautious use.

    Rapid Maxillary Expansion (RME) and orthodontic/orthopedic interventions: synthesis of evidence and recommendations.

    Systematic reviews and meta-analyses report short-term improvements in AHI and oxygen saturation following RME in selected children with transverse maxillary deficiency and narrow/high-arched palate; pooled estimates showed substantial mean reductions in AHI in uncontrolled series (e.g., Camacho et al, 2017).
    Policy Summary
    PayerAetna
    PolicyObstructive Sleep Apnea in Children
    Policy CodePolicy 0752
    Change TypeNo material clinical or coverage changes
    Effective DateApr 25, 2008
    Last ReviewDec 13, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain and document attended nocturnal polysomnography (NPSG) in a facility to support diagnosis or post‑operative assessment and meet coverage criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and Authorization GuidanceBackground and Evidence ContextDefinitionsPolicy Revision History
    Higher-quality comparative evidence is limited: a systematic review identified only one randomized controlled trial comparing RME to watchful waiting and several non-randomized studies comparing RME with adenotonsillectomy. Controlled data did not consistently demonstrate superiority of RME over conservative management.
    Professional guidance (AAP, AAPD) suggests RME may benefit specially selected patients (maxillary constriction/crossbite) but cautions that robust randomized evidence is lacking; watchful waiting or standard therapies remain primary approaches.

    inv-13: Glossectomy/TORS: selective coverage — Tongue-base reduction and glossectomy — evidence summary.

    Tongue-base reduction / glossectomy (including TORS) — summary of evidence and outcomes.

    Systematic reviews and pooled analyses in adults report significant improvements in AHI, ESS, snoring scores, and oxygen saturation when glossectomy or tongue‑base reduction is performed as part of multi-level surgery; reported surgical success rates vary (approx. 59–75% depending on technique and series).
    TORS base-of-tongue reduction studies demonstrated meaningful AHI and symptom improvements with cure rates in the 20–25% range and success rates often above 60%, but are primarily adult series; complication rates and variability in tissue volume resected affect outcomes.
    Pediatric evidence is limited to small case series and reports suggesting feasibility and symptomatic improvement in selected children with lingual tonsil hypertrophy or macroglossia; larger, controlled pediatric studies are lacking.

    inv-14: DNA methylation testing: not_covered_in_clinical_practice — DNA methylation biomarkers — investigational.

    DNA methylation and other epigenetic biomarkers for pediatric OSA — current evidence and limitations.

    Preliminary studies have identified differentially methylated loci and associations between methylation of selected genes (eg, IL1R2, AR, NPR2, SP140, FOXP3, eNOS) and OSA phenotypes or related outcomes, but findings are inconsistent and primarily from small cohorts.
    Existing studies are cross-sectional or limited by small sample sizes, lack of prospective validation, and inability to establish causality; many results derive from secondary analyses or animal models.
    Systematic reviews and expert reviews conclude that epigenetic markers show promise for mechanistic insights and future risk stratification, but there is insufficient evidence for clinical diagnostic or prognostic use at present.

    inv-09: Supraglottoplasty for laryngomalacia — Covered when ALL of the following are met.

    Supraglottoplasty for laryngomalacia — evidence synthesis and outcomes.

    Systematic reviews and meta-analyses report significant reductions in AHI and improvements in lowest oxygen saturation after supraglottoplasty in children with laryngomalacia and associated OSA; relative reductions in AHI are substantial though cure is uncommon in most series.
    Pooled analyses report variable success rates depending on definitions (eg, AHI <1 vs AHI <5), with success often reported in the range of ~28–77% depending on thresholds and subgroups.
    Complications are generally low but residual disease is common; outcomes are most favorable when supraglottoplasty is targeted to children with symptomatic laryngomalacia and objective PSG-confirmed OSA.

    inv-22: COVERAGE CRITERIA — Montelukast and intranasal corticosteroids — evidence summaries relevant to coverage.

    Pharmacologic and intranasal therapies (montelukast, intranasal corticosteroids): evidence and regulatory considerations.

    Meta-analyses of pediatric trials indicate montelukast alone or combined with intranasal corticosteroids can reduce AHI and improve lowest oxygen saturation in short-term studies of mild pediatric OSA; pooled estimates show modest absolute reductions in AHI.
    Recent randomized, placebo-controlled trials of intranasal mometasone (MIST trial) did not demonstrate clinically meaningful benefits over saline for symptom resolution or PSG outcomes at primary endpoints; longer-term or subgroup effects may be limited.
    Montelukast is not FDA-approved for OSA; intranasal corticosteroids are commonly used adjunctively for nasal obstruction or mild disease but randomized evidence for clinically meaningful, durable benefit is mixed.

    Coding and Billing

    Covered CPT Codes — Polysomnography (facility-attended)CPTCovered
    95808Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
    95810Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist [nocturnal].
    95811Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist [nocturnal].
    95782Younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
    95783Younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist.
    Other Sleep/Care CPT and CPAP device codesmixed
    95800Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis and sleep time.
    95801Minimum of heart rate, oxygen saturation, and respiratory analysis.
    95806Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, unattended.
    95807Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
    94660Continuous positive airway pressure ventilation (CPAP), initiation and management.
    94660Continuous positive airway pressure ventilation (CPAP), initiation and management.
    E0601Continuous positive airway pressure (CPAP) device.
    Hypoglossal nerve stimulation — CPT/HCPCS/DRGmixedCovered
    64582Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    64583Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator.
    64584Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    C1767Generator, neurostimulator (implantable), non-rechargeable.
    C1778Lead, neurostimulator (implantable).
    C1787Patient programmer, neurostimulator.
    L8679Implantable neurostimulator, pulse generator, any type.
    L8680Implantable neurostimulator electrode, each.
    L8681Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only.
    L8686Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
    Adenoidectomy and/or tonsillectomy — Covered CPTCPTCovered
    42820-42831Tonsillectomy and adenoidectomy procedures (tonsillectomy and adenoidectomy; various primary/secondary codes).
    42830-42836Adenoidectomy codes (primary and secondary).
    42825-42826Tonsillectomy, primary or secondary.
    Oral appliances — limited coveragemixedCovered
    E0485Oral device/appliance used to reduce upper airway collapsibility, prefabricated, includes fitting and adjustment [covered for children with craniofacial anomalies only].
    E0486Oral device/appliance used to reduce upper airway collapsibility, custom fabricated, includes fitting and adjustment [covered for children with craniofacial anomalies only].
    D9947Custom sleep apnea appliance fabrication and placement.
    D9948Adjustment of custom sleep apnea appliance.
    Home/unattended testing and related codes — not covered for CPB indicationsmixedNot Covered
    G0398Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels.
    G0399Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels.
    G0400Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels.
    D9956Administration of home sleep apnea test.
    D9957Screening for sleep related breathing disorders.
    E0445Oximeter device for measuring blood oxygen levels non-invasively [nocturnal].
    S3900Surface electromyography (EMG).
    Codes related to experimental/investigational procedures — not coveredmixedNot Covered
    20692-20697Multiplane external fixation system (mandibular distraction osteogenesis).
    30801-30999Surgery/Respiratory System, nose/nasal (codes cited as not covered for certain procedures).
    41130Glossectomy; hemiglossectomy.
    41512Tongue base suspension, permanent suture technique (Repose System).
    42140Uvulectomy, excision of uvula.
    42160Destruction of lesion, palate or uvula (thermal, cryo or chemical) [for LAUP].
    42890Limited pharyngectomy.
    42950Pharyngoplasty (expansion sphincter pharyngoplasty) [for CAPSO].
    98940-98943Chiropractic manipulative treatment (CMT).
    98925-98929Osteopathic manipulative treatment (OMT).
    1–10 of 12
    1/2
    Not Covered / explicitly listedmixedNot Covered
    20692-20697Multiplane external fixation system [mandibular distraction osteogenesis]
    30000-30999Surgery/Respiratory System, nose/nasal (range referenced)
    30801Cautery and/or ablation, mucosa of inferior turbinates, unilateral or bilateral, any method; superficial
    30802Intramural (for somnoplasty or coblation)
    41130Glossectomy; hemiglossectomy
    41512Tongue base suspension, permanent suture technique [Repose System]
    42140Uvulectomy, excision of uvula
    42160Destruction of lesion, palate or uvula (thermal, cryo or chemical) [for laser assisted uvuloplasty]
    42890Limited pharyngectomy
    42950Pharyngoplasty (plastic or reconstructive operation on pharynx) [for CAPSO] [expansion sphincter pharyngoplasty]
    1–10 of 18
    1/2
    Apnea-Hypopnea Index (AHI) for UAS candidacy — numeric threshold
    AHI range for UAS candidacy>10 and <50 events/hour
    PurposeFDA-specified AHI eligibility for hypoglossal nerve neurostimulation in adolescents with Down syndrome
    ContextCombined with other FDA criteria: age 13–18, absence of complete concentric collapse, prior adenotonsillectomy consideration, and failed/intolerant PAP
    Age for UAS in Down syndrome — numeric age window
    Age window13-18 years
    IndicationFDA-specified age range for hypoglossal nerve neurostimulation (UAS) in adolescents with Down syndrome
    Combined requirementAge must be met along with AHI >10 and <50 and other FDA criteria
    Obstructive apnea index threshold — commonly used normality threshold
    Obstructive apnea index thresholdObstructive apnea index of 1 (often chosen as threshold of normality)
    Source populationNormative pediatric data referenced for children aged 1–15 years
    Interpretation noteInterpretation of NPSG values in children is not unanimously agreed upon in the literature
    Other normative PSG values (children 1–15 yrs)
    Central apnea index (children 1–15 yrs)0.9 events/hour
    Oxygen desaturation nadir89%
    Baseline oxygen saturation92%
    PETCO2 criterionPETCO2 >45 mm Hg for <10% of total sleep time
    Moderate-to-severe OSA eligibility — AHI > 15 events/hour (study threshold)
    Study threshold for moderate-to-severe OSAAHI > 15 events/hour
    ContextUsed as eligibility cutoff in TORS-TBR study for moderate-to-severe OSA
    Associated criteriaTypically applied with DISE-confirmed tongue-base collapse and CPAP failure in that study population
    Cure definition (RME meta-analysis subgroup) — AHI < 1/hour
    Cure definition in RME subgroup analysesAHI < 1 event/hour
    Reported cure rate~25.6% for subset of 90 patients where calculable
    ContextUsed in RME systematic review/meta-analysis to define 'cure' in some analyses
    Prior auth — hypoglossal nerve stimulation (UAS) — callout-level billing requirement noted in coding section
    Prior authorization implicationPrior authorization is implied for implantation, revision, or removal of hypoglossal nerve neurostimulator and associated implantable device codes when selection criteria are met
    Relevant CPT/HCPCS codesExamples include 64582-64584, C1767, L8679, L8680, L8681, L8686 (see coding section)
    Documentation requiredClinical documentation should confirm FDA criteria: age 13–18, Down syndrome, AHI >10 and <50, absence of complete concentric collapse, prior adenotonsillectomy consideration, and failed/intolerant PAP

    Provider Actions and Authorization Guidance

    Prior Authorization

    RME prior authorization rationale

    Rapid maxillary expansion (RME) for pediatric OSA may be subject to local plan authorization. Prior authorization for RME should include documentation of transverse maxillary constriction (e.g., narrow/high-arched palate or crossbite), baseline AHI, prior adenotonsillectomy status (if performed), and a discussion that RME evidence is limited and randomized data do not convincingly show benefit over watchful waiting. Consideration should be given to the dental/orthodontic benefit exclusion in many medical plans; verify member benefits prior to authorization.

    • Document transverse maxillary deficiency (narrow/high-arched palate)
    • Provide baseline AHI and prior AT status
    • Discuss limited RCT evidence and potential dental benefit exclusion
    Documentation Required

    Pre-operative counseling and post-operative monitoring documentation

    Children with cerebral palsy (and other high-risk conditions) undergoing adenotonsillectomy should have documented pre-operative counseling about increased peri-operative respiratory risks and a documented post-operative monitoring plan. Authorization and care plans should reflect the need for close inpatient observation, higher risk of respiratory complications, and discussion of possible additional surgical management (including tracheostomy) if OSA persists.

    • Document counseling of family regarding increased peri-operative risk
    • Document plan for close post-operative monitoring and potential ICU care
    • Note possibility of further interventions if OSA persists
    Note

    Prior authorization not specified in this section

    This section does not itself establish new prior authorization rules for all procedures or devices listed elsewhere in the policy. Providers must follow specific plan provisions and pre-authorization tools for the member's benefit plan.

    • Check the member's benefit plan for any applicable prior authorization requirements
    • Use plan-specific authorization portals or contact the plan for clarification
    Note

    Prior authorization guidance

    Clinical Policy Bulletins are intended to assist administration of plan benefits and do not replace plan-specific requirements. Providers should follow the health plan's procedures for prior authorization, billing, and documentation; if in doubt, obtain prior authorization before performing services.

    • CPBs do not constitute a contract or guarantee of coverage
    • Obtain plan-specific prior authorization when required
    Denial Risk

    Noncovered procedures / code denials (denial risk)

    Procedures and services listed in the policy as not covered or considered experimental/investigational are denial risks if submitted for those indications. Verify coding and indications against the CPB before authorization or claim submission.

    • Examples of not-covered CPT ranges: 30000-30999 (nasal surgeries), 30801-30802 (somnoplasty), 41130 (hemiglossectomy), 41512 (Repose system tongue suspension), 42140/42160 (uvulectomy/destruction of palate/uvula), 42890/42950 (pharyngeal procedures)
    • Montelukast has no specific HCPCS/CPT code listed and use for OSA is off-label (see montelukast callouts)
    Prior Authorization

    Regulatory and prior‑therapy context for hypoglossal nerve stimulation (HNS)

    For hypoglossal nerve stimulation (HNS/UAS) in pediatric patients, document that FDA criteria and prior-therapy conditions are met: age 13–18, Down syndrome diagnosis, AHI >10 and <50, absence of complete concentric collapse at the soft palate, contraindication to or ineffective adenotonsillectomy, and confirmed failure or intolerance of PAP despite attempts to improve compliance. Prior use of standard therapies and consideration of alternative/adjunct treatments should be evident in the record.

    • Age documented (13–18 years) and diagnosis of Down syndrome
    • Baseline AHI and documentation of lack of complete concentric collapse (e.g., DISE)
    • Documentation of adenotonsillectomy contraindication or failure
    • Evidence of PAP failure or intolerance and attempts to improve compliance
    • Notes on consideration of other therapies
    Denial Risk

    RME evidence insufficiency (denial risk)

    The evidence base for RME is mixed: uncontrolled case series show short‑term improvements but controlled randomized data are sparse and one RCT did not show superiority versus watchful waiting. Because long‑term effects and reproducibility are uncertain, payers may deny coverage without strong, patient‑specific documentation supporting use.

    • Cite RME studies showing short‑term AHI and LSAT improvements in selected patients
    • Note lack of convincing RCT evidence and need for reproducible inclusion criteria
    Denial Risk

    Montelukast — off‑label use risk and documentation

    Montelukast and intranasal corticosteroids have shown short‑term improvements in AHI in some trials for mild pediatric OSA, but montelukast is not FDA‑approved for OSA and use is off‑label. Document indication, duration, expected benefit, and monitor for adverse effects (including behavioral changes). Authorization or coverage may be scrutinized given off‑label status.

    • Document diagnosis of mild OSA and rationale for medical therapy
    • Record baseline and follow-up PSG/AHI when available
    • Monitor and document adverse effects (e.g., behavioral side effects)
    Documentation Required

    Incomplete PSG documentation can affect coverage decisions

    Incomplete or absent pre‑ or post‑operative polysomnography (PSG/NPSG) can affect coverage decisions and the applicability of evidence. When studies cited in support of interventions lack complete PSG data, plans may require objective testing (pre‑ and/or post‑op PSG) to substantiate medical necessity and outcomes.

    • Provide pre‑operative PSG when indicated by policy or clinical circumstance
    • Provide post‑operative PSG for high‑risk patients or when residual symptoms persist (timing per policy recommendations)
    • Document reasons if PSG cannot be obtained and alternative objective data
    Note

    Background / not directly applicable to authorization

    Background sections and some referenced studies do not directly create coverage rules. Use the background evidence to support medical necessity decisions, but rely on the policy criteria and plan benefits for authorization determinations.

    • Background evidence informs but does not replace policy criteria
    • Follow the policy's documented selection criteria for covered services
    Documentation Required

    Polysomnography documentation (diagnosis and post‑op)

    Polysomnography (PSG/NPSG) is the gold standard for diagnosis and monitoring of pediatric OSA. For authorization, document that PSG was facility‑based, attended by a technologist, and interpreted by a qualified physician, and that the indication for testing matches policy criteria (diagnostic reasons or post‑operative assessment).

    • Confirm facility‑based, attended overnight PSG/NPSG
    • Record the specific indication for testing per policy (diagnosis, post‑op assessment, etc.)
    • Attach physician interpretation and technologist attendance notes
    Prior Authorization

    Required clinical documentation for HNS candidacy

    When requesting authorization for hypoglossal nerve stimulation (HNS/UAS), include the required clinical documentation to establish candidacy: patient age, diagnosis (Down syndrome), baseline AHI, DISE findings ruling out complete concentric collapse at the soft palate, documentation of prior adenotonsillectomy status or contraindication, and detailed records of PAP therapy failure or intolerance and measures taken to improve adherence.

    • Age 13–18 and Down syndrome diagnosis documented
    • Baseline AHI (>10 and <50) with supporting PSG
    • DISE or equivalent documentation demonstrating absence of complete concentric collapse at the soft palate
    • Records of adenotonsillectomy status or contraindication
    • Detailed documentation of PAP trials, adherence efforts, and intolerance
    Documentation Required

    RME patient selection and follow‑up documentation

    For RME patient selection and follow‑up, document transverse maxillary deficiency (narrow/high‑arched palate or crossbite), baseline PSG/AHI, prior adenotonsillectomy status, orthodontic treatment plan, and follow‑up sleep testing or clinical assessments to demonstrate response and durability.

    • Document transverse maxillary deficiency and orthodontic diagnosis
    • Provide baseline AHI and plan for follow‑up PSG or objective assessment
    • State prior AT status and rationale for RME as adjunctive therapy
    Documentation Required

    TORS‑TBR documentation requirements

    For TORS‑TBR (transoral robotic surgery tongue‑base resection) with tongue‑base suspension, include documentation of DISE‑confirmed tongue‑base collapse, preoperative AHI demonstrating moderate‑to‑severe OSA (e.g., AHI >15 in cited studies), and prior failure of CPAP. Discuss expected benefits, risks, and alternative therapies in the record.

    • DISE confirming tongue‑base collapse and glossoptosis
    • Preoperative AHI and severity documented
    • Evidence of CPAP failure or intolerance
    • Informed consent noting expected benefits/risks and potential additional procedures
    Note

    Provider responsibility for medical advice and treatment

    Treating providers are solely responsible for medical advice and treatment decisions. Clinical Policy Bulletins are informational and do not replace clinical judgment. When submitting authorization requests, ensure documentation supports the clinical decision and plan adherence to policy criteria.

    • Providers must document clinical rationale and informed consent
    • Use CPB as guidance but rely on clinical judgment for patient care
    Step Therapy

    Medical therapy (montelukast / intranasal steroid) as an initial option

    Medical therapy (e.g., montelukast, intranasal steroids) may be appropriate as an initial option for selected children with mild OSA or as temporizing therapy while awaiting other interventions. When used, document indication, planned duration, monitoring, and criteria for escalation to surgical or CPAP therapy.

    • Document mild OSA diagnosis and rationale for medical therapy
    • Record planned duration and monitoring strategy
    • Specify criteria for escalation to surgery or CPAP

    Background and Evidence Context

    Pediatric obstructive sleep apnea (OSAS) is commonly associated with adenotonsillar hypertrophy and may be associated with obesity, craniofacial anomalies, neuromuscular disorders (including Down syndrome), and other comorbidities. Nocturnal polysomnography (NPSG) performed in a facility with technologist attendance and physician interpretation is the gold‑standard diagnostic test to differentiate OSAS from primary snoring and to guide management and post‑operative assessment.

    Definitions

    Nocturnal polysomnography (NPSG)
    DefinitionAttended sleep study performed in a healthcare facility for diagnosis of OSAS and other listed sleep disorders in children and adolescents younger than 18
    Indications (examples)To diagnose OSAS and differentiate from snoring; evaluate hypersomnia; suspected narcolepsy (with MSLT); parasomnia; restless leg syndrome; periodic limb movement disorder; congenital central alveolar hypoventilation; sleep-related hypoventilation due to neuromuscular or chest wall disorders
    Post-operative timingWhen performed after adenotonsillectomy or pharyngeal surgery, study should be delayed 6 to 8 weeks post-operatively
    Hypoglossal nerve neurostimulation (UAS)
    DefinitionFDA-approved implantable upper airway stimulation therapy (e.g., Inspire systems) indicated for adolescents with Down syndrome meeting specified criteria
    MechanismImplantable device electrically stimulates the hypoglossal nerve to contract the genioglossus and prevent airway collapse during sleep
    Coverage caveatCoverage only when all FDA-specified clinical criteria (age, AHI range, airway collapse pattern, prior therapies) are met
    Primary snoring
    DefinitionSnoring without obstructive apnea, frequent arousals, or abnormalities in gaseous exchange
    Prevalence noteEstimated 3%–12% of children are habitual snorers, but only ~2% diagnosed with OSAS
    Clinical implicationPrimary snoring warrants careful screening to differentiate from OSAS
    Polysomnogram (PSG)
    DefinitionAn attended, facility-based overnight sleep study recording multiple physiologic channels (minimum 12 channels) to quantify ventilatory and sleep parameters
    PurposeUsed to diagnose OSAS, differentiate primary snoring, and quantify severity for treatment planning
    Interpretation caveatPediatric NPSG value interpretation is not universally agreed and normative datasets are limited
    Hypoglossal nerve stimulation (HNS)
    DefinitionAn implantable programmable device that electrically stimulates the hypoglossal nerve to contract the genioglossus muscle, preventing airway collapse
    Clinical useUsed as upper airway stimulation therapy for OSA in selected patients who meet device and clinical criteria
    Device examplesInspire UAS systems referenced as FDA-approved devices
    Rapid maxillary expansion (RME)
    DefinitionAn orthodontic treatment intended to expand the maxillary arch evaluated for pediatric OSA (transverse maxillary deficiency)
    Evidence contextMultiple small studies and meta-analysis report short-term AHI and LSAT improvements, but randomized evidence is limited
    Coverage stanceConsidered with caveats; documentation of maxillary constriction and prior treatments recommended
    Cure (in RME studies)
    Definition (study use)AHI < 1 event/hour used as 'cure' in some RME study analyses
    ContextApplied in meta-analysis subgroup to report cure rates after RME
    Related metricCure rate reported ~25.6% in subset where calculable
    Moderate-to-severe OSA (study threshold)
    Definition (study threshold)Moderate-to-severe OSA defined as AHI > 15 events/hour in the referenced TORS-TBR study
    ContextUsed as eligibility criterion in that surgical trial; often paired with DISE-confirmed tongue-base collapse and CPAP failure
    ImplicationIndicates a higher severity threshold for selecting patients for multi-level surgical interventions
    Epigenetic markers / DNA methylation
    DefinitionAlterations in DNA methylation patterns (e.g., IL1R2, AR, NPR2, SP140, FOXP3, eNOS) proposed as biomarkers associated with OSA severity and outcomes
    Evidence statusPreliminary and investigational; findings are not validated for clinical use
    Clinical stanceEpigenetic/DNA methylation testing is investigational and not established for diagnosis or prognosis
    sEMGcw (surface EMG of chest wall)
    DefinitionNon-normalized surface electromyography over the lateral chest wall used as an index of neural respiratory drive (sEMGcw)
    FindingssEMGcw values were higher in children with OSA and those with increased work of breathing compared with primary snorers
    Clinical statusPreliminary utility as a non-invasive marker; requires further validation before routine clinical use
    Apnea-Hypopnea Index (AHI)
    DefinitionA polysomnography-derived measure of apneas and hypopneas per hour of sleep; used to define OSA severity and treatment success
    Use in studiesReported across RME, supraglottoplasty, HNS, and other interventions as primary outcome (AHI/OAHI)
    Interpretation caveatPediatric AHI interpretation varies across studies and normative thresholds are limited
    Tissue Doppler Imaging (TDI)
    DefinitionAn echocardiographic technique quantifying myocardial motion velocities to evaluate cardiac function (TDI)
    Study findingsTDI detected subclinical changes in children with OSA that normalized after tonsillectomy/adenoidectomy in some studies
    Clinical implicationTDI may detect subclinical cardiac dysfunction but routine pre-op use is not yet established
    OAHI / OAHI change
    DefinitionObstructive apnea-hypopnea index (OAHI) as measured by PSG; change in OAHI/OAHI commonly used as primary outcome in intervention trials
    Trial examplesUsed as primary outcome in INCS and other pediatric trials (e.g., Tapia et al., MIST trial) to assess treatment effect
    InterpretationSmall absolute changes may be statistically significant but not clinically meaningful; correlate with symptoms and outcomes
    SDB Score (symptom resolution)
    DefinitionParental report instrument used to define resolution of significant sleep-disordered breathing symptoms in the MIST trial (per AAP referral criteria)
    Outcome usePrimary outcome in MIST trial was resolution of significant SDB symptoms measured by SDB Score at 6 weeks
    Clinical implicationSymptom-based measures may show similar outcomes between interventions and placebo; nearly half of referred children may be managed in primary care

    Policy Revision History